Patients with active facial acne of mild-to-moderate severity (Global Acne Grading Scale [GAGS] score from 1 to 30) [14 (link), 15 (link)] were eligible for inclusion. Subjects were excluded if they had previously received oral retinoids, oral antibiotics, tretinoin, or benzoyl peroxide. In addition, patients with diabetes mellitus, endocrine disease, or severe physical illnesses and those who were currently using oral contraceptives, implantable contraceptives, or steroids were excluded [16 ]. All participants involved in the microbiological and clinical investigations were asked to withdraw any topical product 14 days before the beginning of the studies. Moreover, they were not allowed to use any topical intervention throughout the entire study period. The study participants were instructed to apply the topical cream over acne areas twice per day (morning and evening) for 60 days in the microbiological study and for 8 weeks in the clinical study. There were no known protocol deviations during the study. Both investigations were approved by the local Ethics Committee (identifier: 2021/14E) and were in accordance with the tenets of the Helsinki Declaration. Written informed consent was obtained from all participants.